Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 20 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 1 20 versus PORTIA 21.
GILDESS 1/20 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive